home / stock / akro / akro news

AKRO News and Press, Akero Therapeutics Inc. From 05/02/22

Stock Information
Company Name: Akero Therapeutics Inc.
Stock Symbol: AKRO
Market: NYSE
Website: akerotx.com
Menu
AKRO AKRO Quote AKRO Short AKRO News AKRO Articles AKRO Message Board
Get AKRO Alerts

News, Short Squeeze, Breakout and More Instantly...
AKRO - Akero Therapeutics to Present at Upcoming Healthcare Conferences in May

SOUTH SAN FRANCISCO, May 02, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will parti...
AKRO - Akero Therapeutics GAAP EPS of -$0.93 misses by $0.13

Akero Therapeutics press release (NASDAQ:AKRO): Q4 GAAP EPS of -$0.93 misses by $0.13. Akero's cash, cash equivalents and short-term marketable securities for the year ended December 31, 2021 were $188.3 million. Akero believes that its cash, cash equivalents and short-term mar...

AKRO - Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and...

AKRO - Akero finishes enrollment in phase 2b trial of efruxifermin in liver disease

Akero Therapeutics (AKRO -0.2%) completed enrollment in a phase 2b study, dubbed HARMONY, evaluating efruxifermin (EFX) to treat non-alcoholic steatohepatitis (NASH). "Our confidence in EFX’s potential is based on Phase 2a data that showed substantial rates of fibrosis regres...
AKRO - Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that it has compl...

AKRO - JAKK, AFRM and AKRO among after hour movers

Gainers: Amazon.com AMZN +14%. JAKKS Pacific (NASDAQ:JAKK) +11%. Aurora Innovation AUR +10%. Affirm Holdings (NASDAQ:AFRM) +10%. DLocal Limited (NASDAQ:DLO) +9%. Losers: SkyWest SKYW -6%. Akero Therapeutics (NASDAQ:AKRO) -5%. Dogness (International) Corporation (NASDA...

AKRO - Akero Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management w...
AKRO - Akero Therapeutics to Present at the Evercore ISI 4th Annual HealthCONx Virtual Conference

SOUTH SAN FRANCISCO, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will part...

AKRO - Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment

Most EFX-treated patients with end-of-treatment biopsies showed improvements in features of steatohepatitis (35 of 40; 87%) and/or fibrosis (32 of 40; 80%), after only 16 weeks Histological improvements were evident across all types of patients, including those at higher risk of...

AKRO - Akero Therapeutics EPS beats by $0.16

Akero Therapeutics (NASDAQ:AKRO): Q3 GAAP EPS of -$0.70 beats by $0.16. Cash, cash equivalents and short-term marketable securities for the period ended September 30, 2021 were $215.1M Press Release For further details see: Akero Therapeutics EPS beats by $0.16

Previous 10 Next 10